clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Psoriasis D011565 47 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arthritis D001168 41 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Fever D005334 35 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Diarrhea D003967 32 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Endometriosis D004715 29 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Gastritis D005756 27 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Fibrosis D005355 23 associated lipids
Periodontitis D010518 22 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Myocardial Infarction D009203 21 associated lipids
Bacterial Infections D001424 21 associated lipids
Helicobacter Infections D016481 21 associated lipids
Tuberculosis D014376 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Peptic Ulcer D010437 19 associated lipids
Ischemia D007511 18 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Bronchial Spasm D001986 18 associated lipids
Dermatomycoses D003881 17 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Encephalitis D004660 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Synovitis D013585 15 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Radiation Injuries D011832 14 associated lipids
Rosacea D012393 13 associated lipids
Bradycardia D001919 13 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Abscess D000038 13 associated lipids
Urticaria D014581 13 associated lipids
Otitis Media D010033 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Endophthalmitis D009877 12 associated lipids
Wound Infection D014946 12 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Exanthema D005076 11 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Shock, Septic D012772 11 associated lipids
Influenza, Human D007251 11 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Dyspnea D004417 10 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Hearing Disorders D006311 10 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Hemophilia A D006467 10 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Cross Infection D003428 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Urethritis D014526 9 associated lipids
Sinusitis D012852 9 associated lipids
Urination Disorders D014555 9 associated lipids
Bacteremia D016470 9 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Lymphadenitis D008199 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Grove DI and Koutsouridis G Increasing resistance of Helicobacter pylori to clarithromycin: is the horse bolting? 2002 Pathology pmid:11902451
Midolo PD et al. Antimicrobial resistance testing of Helicobacter pylori: a comparison of Etest and disk diffusion methods. 1997 Pathology pmid:9423225
Schulz S et al. Molecular diagnosis of a Mycobacterium chelonae infection. 2001 Pathol. Res. Pract. pmid:11261816
Okiyama Y et al. Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients. 2005 Pathol. Int. pmid:15982214
Chang WJ et al. Successful salvage treatment of steroid-refractory bronchiolar COP with low-dose macrolides. 2012 Pathol. Int. pmid:22243785
Suzuki T et al. Localization of antigen-presenting cells in Helicobacter pylori-infected gastric mucosa. 2002 Pathol. Int. pmid:12031081
Ploy MC et al. [Antibacterial activity of clarithromycin and its hydroxylated derivative and two other macrolides against thirty strains of Streptococcus pneumoniae]. 1994 Pathol. Biol. pmid:7824300
Gevaudan MJ et al. [Evaluation of the extra- and intracellular activity of clarithromycin against Mycobacterium chelonae]. 1994 Pathol. Biol. pmid:7824305
Dauendorffer JN et al. In vitro sensitivity of Mycobacterium xenopi to five antibiotics. 2002 Pathol. Biol. pmid:12504367
Ximenes E et al. [Ciprofloxacin, clarithromycin, rifampin: in vitro bactericidal activity of double and triple drug combinations against strains of atypical mycobacteria]. 1993 Pathol. Biol. pmid:8233629
Dabernat H et al. [in vitro activity of telithromycin against Haemophilus influenzae]. 2002 Pathol. Biol. pmid:11873632
Heurtin C et al. [Comparative study of the bacteriostatic and bactericidal activity of levofloxacin against Pasteurella strains isolated from man]. 2001 Pathol. Biol. pmid:11692747
Mariani-Kurkdjian P et al. [Emergence of macrolide resistant Streptococcus pyogenes strains in pediatric patients in France]. 2004 Pathol. Biol. pmid:15465270
Géhanno P et al. [Clarithromycin versus amoxicillin-clavulanic acid in the treatment of acute maxillary sinusitis in adults]. 1996 Pathol. Biol. pmid:8763594
Tankovic J et al. Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. 2001 Pathol. Biol. pmid:11642014
Rodríguez-Sevilla G et al. Influence of three-dimensional lung epithelial cells and interspecies interactions on antibiotic efficacy against Mycobacterium abscessus and Pseudomonas aeruginosa. 2018 Pathog Dis pmid:29648588
Masuda H et al. Characteristics and trends of clarithromycin-resistant Helicobacter pylori isolates in Japan over a decade. 2004 Pathobiology pmid:15051929
Tripathi R et al. Clarithromycin, a cytochrome P450 inhibitor, can reverse mefloquine resistance in Plasmodium yoelii nigeriensis- infected Swiss mice. 2011 Parasitology pmid:21756423
Pandey SK et al. Antimalarial interaction of quinine and quinidine with clarithromycin. 2013 Parasitology pmid:23137860
Hemphill A et al. Treatment of echinococcosis: albendazole and mebendazole--what else? 2014 Parasite pmid:25526545
Fagoonee S et al. Efficacy of cefixime-based triple therapy for Helicobacter pylori eradication: a retrospective study. 2013 Panminerva Med pmid:24088806
Cisarò F et al. Ranitidine bismuth citrate in the first-line of Helicobacter pylori treatment. 2011 Panminerva Med pmid:21659979
Ribaldone DG et al. Efficacy of amoxycillin and clarithromycin-based triple therapy for Helicobacter pylori eradication: a 10-year trend in Turin, Italy. 2015 Panminerva Med pmid:25971330
Tursi A et al. Evaluation of the efficacy and tolerability of four different therapeutic regimens for the Helicobacter pylori eradication. 1996 Panminerva Med pmid:9009677
Barbon V On the efficacy of macrolide-based therapy for Helicobacter pylori infection. 2009 Panminerva Med pmid:19352310
Palmas F et al. Eradication of Helicobacter pylori infection with proton pump inhibitor-based triple therapy. A randomised study. 2002 Panminerva Med pmid:12032434
Tursi A et al. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. 2014 Panminerva Med pmid:24637473
Khan MK et al. Bioequivalence study of two oral formulations of clarithromycin in human male subjects. 2011 Pak J Pharm Sci pmid:21190917
Faraji F et al. The effect of Helicobacter pylori eradication on migraine: a randomized, double blind, controlled trial. 2012 Nov-Dec Pain Physician pmid:23159967
Shinkai M and Rubin BK Macrolides and airway inflammation in children. 2005 Paediatr Respir Rev pmid:16153572
Wood N and McIntyre P Pertussis: review of epidemiology, diagnosis, management and prevention. 2008 Paediatr Respir Rev pmid:18694712
Korppi M Community-acquired pneumonia in children: issues in optimizing antibacterial treatment. 2003 Paediatr Drugs pmid:14658923
Capitano B et al. Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children. 2001 Paediatr Drugs pmid:11706922
Zar HJ Neonatal chlamydial infections: prevention and treatment. 2005 Paediatr Drugs pmid:15871630
Hoigné-Löpfe I and Jöhr M Psychiatric symptoms after anesthesia: antibiomania or Hoigné's syndrome? 2006 Paediatr Anaesth pmid:16618314
Przybylo HJ et al. Acute psychosis after anesthesia: the case for antibiomania. 2005 Paediatr Anaesth pmid:16029408
Hayashi Y et al. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. 1999 Pacing Clin Electrophysiol pmid:10234723
Hassmann-Poznańska E et al. [Efficacy of clarithromycin (Fromilid) in treatment of uncomplicated acute bacterial rhinosinusitis in children]. 2003 Otolaryngol Pol pmid:15049183
Denys A [Theoretical basis for the antibiotic therapy of the upper part of the respiratory system]. 1997 Otolaryngol Pol pmid:9757681
Kubas G and Gospodarek T [The use of clarithromycin and amoxycillin in pediatric acute otitis media]. 1997 Otolaryngol Pol pmid:9757683
Cervin A et al. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effects on mucociliary parameters and nasal nitric oxide. 2002 Otolaryngol Head Neck Surg pmid:12075221
Fraser L et al. Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review. 2008 Otolaryngol Head Neck Surg pmid:18312877
Tatar EÇ et al. Prevalence of biofilms and their response to medical treatment in chronic rhinosinusitis without polyps. 2012 Otolaryngol Head Neck Surg pmid:22241786
Buzás GM and Józan J [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002]. 2004 Orv Hetil pmid:15559530
Prónai L and Tulassay Z [Failure of Helicobacter pylori eradication--suggestions for further therapy]. 2003 Orv Hetil pmid:12894674
Buzás GM [Helicobacter pylori -- 2010]. 2010 Orv Hetil pmid:21106480
Buzás GM et al. [The epidemiology of clarithromycin resistance of Helicobacter pylori infection in Hungary]. 2007 Orv Hetil pmid:17656336
Herszényi L [Eradication of Helicobacter pylori]. 2003 Orv Hetil pmid:14626641
Szántó D et al. [Could Helicobacter pylori cause reactive arthro-osteitis?]. 1997 Orv Hetil pmid:9340585
Hagymási K and Tulassay Z [The new aspects of the eradication of Helicobacter pylori and the importance of bacterial resistance]. 2008 Orv Hetil pmid:18926961
Buzás GM [Helicobacter pylori - 2012]. 2012 Orv Hetil pmid:22951408
Buzás György M et al. [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. 2000 Orv Hetil pmid:10976194
Buzás GM [The effect of Helicobacter pylori eradication on prokinetic treatment on the quality of life in functional dyspepsia]. 2004 Orv Hetil pmid:15566071
Lengyel G and Zsolt T [Failure in the eradication of Helicobacter pylori: the role of antibiotic resistance]. 2005 Orv Hetil pmid:15926629
Bózsik BP [Comment on Borrelia burgdorferi Group infections]. 2002 Orv Hetil pmid:12073543
Mazis GA et al. Recurrent fluctuant mass of the wrist and forearm associated with chronic tenosynovitis by Mycobacterium kansasii. 2011 Orthopedics pmid:21598885
Suzuki H et al. Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. 2000 May-Jun ORL J. Otorhinolaryngol. Relat. Spec. pmid:10810255
Luo Q et al. Evaluation of long-term clarithromycin treatment in adult Chinese Patients with chronic rhinosinusitis without nasal polyps. 2011 ORL J. Otorhinolaryngol. Relat. Spec. pmid:21757966
Namiot Z et al. Effect of antibacterial therapy and salivary secretion on the efficacy of Helicobacter pylori eradication in duodenal ulcer patients. 2004 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:15184853
Avcu N et al. The relationship between gastric-oral Helicobacter pylori and oral hygiene in patients with vitamin B12-deficiency anemia. 2001 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:11505263
Lindeboom JA et al. First case of an oculofacial lesion due to Mycobacterium haemophilum infection in an immunocompetent child. 2006 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:16731399
Lindeboom JA et al. Clarithromycin as a single-modality treatment in mycobacterial avium-intracellular infections. 1999 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:9927080
Freitas D et al. An outbreak of Mycobacterium chelonae infection after LASIK. 2003 Ophthalmology pmid:12578767
Solomon A et al. Mycobacterium interface keratitis after laser in situ keratomileusis. 2001 Ophthalmology pmid:11733259
Klapper SR et al. Atypical mycobacterial infection of the orbit. 1995 Ophthalmology pmid:9097803
Klapper SR and Patrinely JR Periocular atypical mycobacterial infections. 1999 Ophthalmology pmid:10485521
Hamam RN et al. Recalcitrant post-LASIK Mycobacterium chelonae keratitis eradicated after the use of fourth-generation fluoroquinolone. 2006 Ophthalmology pmid:16647126
Karia N and Aylward GW Postoperative proprionibacterium acnes endophthalmitis. 2001 Ophthalmology pmid:11297461
Bhagat N et al. Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. 2001 Ophthalmology pmid:11297492
Krasny J et al. The Relationship between chlamydia trachomatis and chlamydia pneumoniae as the cause of neonatal conjunctivitis (ophthalmia neonatorum). 2005 Jul-Aug Ophthalmologica pmid:16088243
Auw-Hädrich C et al. [Clarithromycin for monotherapy of B-cell MALT lymphoma?]. 2013 Ophthalmologe pmid:24231914
Haas K [Reply]. 2013 Ophthalmologe pmid:24377112
Danilko L et al. [Clarithromycin therapy of a B cell MALT lymphoma]. 2013 Ophthalmologe pmid:23224128
Holzer MP et al. [Diagnosis and treatment of mycobacterial keratitis following LASIK. Case report and review of the literature]. 2003 Ophthalmologe pmid:12920556
Mauriello JA Atypical mycobacterial infection of the periocular region after periocular and facial surgery. 2003 Ophthalmic Plast Reconstr Surg pmid:12918551
Omurzakova NA et al. Prevalence of Group A b-Hemolytic Streptococcus Among Children with Tonsillopharyngitis in Kyrgyzstan: The Difficulty of Diagnostics and Therapy. 2010 Open Rheumatol J pmid:21253454
Mc Laughlin AM et al. Extensively drug-resistant tuberculosis (XDR-TB) - a potential threat in Ireland. 2007 Open Respir Med J pmid:19340317
Fortún J et al. Ca-125: a useful marker to distinguish pulmonary tuberculosis from other pulmonary infections. 2009 Open Respir Med J pmid:19966922
Abdalla Abbas M et al. Microbial risk factors of cardiovascular and cerebrovascular diseases: potential therapeutical options. 2008 Open Neurol J pmid:19018303
Eber E Treatment of acute viral bronchiolitis. 2011 Open Microbiol J pmid:22262989
Lee C et al. A patient with shortness of breath and bilateral pulmonary infiltrates. 2010 Open Med pmid:21687339
Feeney ER and Mallon PW HIV and HAART-Associated Dyslipidemia. 2011 Open Cardiovasc Med J pmid:21643501
Clarithromycin effectively treats infection in AIDS patients. 1993 Oncology (Williston Park, N.Y.) pmid:8512782
Adachi T et al. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori. 2017 Oncology pmid:29258111
Hiyama T et al. c-myc gene mutation in gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma. 2001 Mar-Apr Oncol. Rep. pmid:11182042
Hiyama T et al. Microsatellite instability at D18S61 is associated with no regression of gastric mucosa-associated lymphoid tissue lymphoma after Helicobacter pylori eradication. 2001 Mar-Apr Oncol. Rep. pmid:11182043
Madi D et al. Successful treatment of cerebral toxoplasmosis with clindamycin: a case report. 2012 Oman Med J pmid:23074553
Liu DT et al. Stenotrophomonas maltophilia and Mycobacterium chelonae coinfection of the extraocular scleral buckle explant. 2007 Nov-Dec Ocul. Immunol. Inflamm. pmid:18085488
Stewart MW et al. Visual recovery following Mycobacterium chelonae endophthalmitis. 2006 Ocul. Immunol. Inflamm. pmid:16766402
Barros S et al. Cat Scratch Disease: Not a Benign Condition. 2018 Ocul. Immunol. Inflamm. pmid:28665750
Yamauchi Y et al. Conjunctival flora in patients with human immunodeficiency virus infection. 2005 Jul-Aug Ocul. Immunol. Inflamm. pmid:16159721
Abdullahi M et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). 2008 Obes Surg pmid:18443890
Cerqueira RM et al. Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery--fourteen days superior to seven days? 2011 Obes Surg pmid:20838918
Callen EC and Kessler TL Mycobacterium fortuitum infections associated with laparoscopic gastric banding. 2011 Obes Surg pmid:20336391
Cerqueira RM et al. Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. 2018 Obes Surg pmid:29076008
Cerqueira RM et al. How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery? 2016 Obes Surg pmid:26467690
Cerqueira RM et al. Cumulative Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery. 2013 Obes Surg pmid:23054570
Bonfigli AR et al. Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. 2016 Nutr Metab Cardiovasc Dis pmid:27480449
Bibi Z Role of cytochrome P450 in drug interactions. 2008 Nutr Metab (Lond) pmid:18928560
Kiani J and Imam SZ Medicinal importance of grapefruit juice and its interaction with various drugs. 2007 Nutr J pmid:17971226